公开(公告)号：US11510897B2

公开(公告)日：2022-11-29

申请号：US17024601

申请日：2020-09-17

Applicant: CANOPY GROWTH CORPORATION

Inventor： Kurt Aron Levy

IPC: A61K31/355 ,  A61K31/335 ,  A61K31/353 ,  A61K9/107 ,  A61K31/352 ,  A61K9/08 ,  A61K31/015 ,  A61K31/045 ,  A61K31/122 ,  A61K31/192 ,  A61K31/01 ,  A61K47/22 ,  A61K36/185 ,  A61K31/05 ,  A61K45/06 ,  A61K31/105 ,  A61K31/065

Abstract: This disclosure relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

公开(公告)号：US11406606B2

公开(公告)日：2022-08-09

申请号：US17570683

申请日：2022-01-07

Applicant: ZOGENIX INTERNATIONAL LIMITED

Inventor： Stephen J. Farr ,  Brooks Boyd

IPC: A61K31/137 ,  A61K45/06 ,  A61K31/36 ,  A61K31/551 ,  A61K31/05 ,  A61K31/105

Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

公开(公告)号：US11377370B2

公开(公告)日：2022-07-05

申请号：US16873801

申请日：2020-07-13

Applicant: Teresita Amponin Canuto

Inventor： Teresita Amponin Canuto

IPC: C02F1/28 ,  A61K31/105 ,  C01B33/22 ,  B01J20/20 ,  C02F103/08 ,  C02F103/00

Abstract: A portable small water turbine with activated carbon water filter is described that has material available to conduct the removal of the ionic surfactants of polluted water from seas and rivers. The portable small water turbine is placed inside a mini boat that is remote controlled. The mini boat (similar to adult/kids RC toy boat) can be dropped-off and picked up from the sea or rivers by a drone. The activated carbon water filter tube contains carbon pads composed of mantle peridotite carbon mineralization based activated carbon.

公开(公告)号：US20210353589A1

公开(公告)日：2021-11-18

申请号：US17387875

申请日：2021-07-28

Applicant: CANOPY GROWTH CORPORATION

Inventor： Kurt Aron Levy

IPC: A61K31/353 ,  A61K9/107 ,  A61K31/352 ,  A61K9/08 ,  A61K31/015 ,  A61K31/045 ,  A61K31/122 ,  A61K31/192 ,  A61K31/01 ,  A61K47/22 ,  A61K36/185 ,  A61K31/05 ,  A61K45/06 ,  A61K31/105 ,  A61K31/065 ,  A61K31/355

Abstract: This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heating material to a first temperature and a second temperature.

公开(公告)号：US20210108228A1

公开(公告)日：2021-04-15

申请号：US17128736

申请日：2020-12-21

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： Dan PEER ,  Shiri WEINSTEIN ,  Itai Antoine TOKER ,  Srinivas RAMISHETTI

IPC: C12N15/88 ,  A61K39/395 ,  C07K16/28 ,  A61K47/68 ,  A61K31/7105 ,  A61K31/713 ,  A61K31/105 ,  A61K47/69 ,  A61P35/02 ,  A61K9/00 ,  A61K9/51 ,  A61K48/00

Abstract: Disclosed are targeted lipid based particles for delivery of nucleic acid molecules (such as siRNA) to leukocytes (such as T-Cells and B-cells). Further disclosed are uses of the targeted lipid based particles for treating Leukocytes-associated diseases, such as, cancer.

公开(公告)号：US20200246281A1

公开(公告)日：2020-08-06

申请号：US16811172

申请日：2020-03-06

Applicant: ZOGENIX INTERNATIONAL LIMITED

Inventor： Stephen J. FARR ,  BROOKS BOYD

IPC: A61K31/137 ,  A61K31/05 ,  A61K31/551 ,  A61K31/36 ,  A61K45/06 ,  A61K31/105

Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.

公开(公告)号：US10675253B2

公开(公告)日：2020-06-09

申请号：US15935581

申请日：2018-03-26

Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

Inventor： Christopher Kevil ,  Sibile Pardue

IPC: A61K31/105 ,  A61K38/44 ,  G01N33/84 ,  A61P9/10 ,  A61K33/00

Abstract: Methods and therapeutics for treating nitric oxide (NO) mediated condition comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via DADS. Method and devices for measuring an amount of nitrite in a sample comprising obtaining a sample, adding diallyl disulfide (DADS) to the sample, measuring a post DADS amount of nitric oxide (NO) in the sample, and using the post DADS amount of NO in the sample to determine the amount of nitrite in the sample. Methods and therapeutics for diagnosing and treating critical limb ischemia (CLI) versus non-critical limb ischemic peripheral artery disease (PAD) in a patient comprising determining a patient indicator value, where the patient indicator is value one of a total hydrogen sulfide metabolite plasma level, a total nitric oxide, nitrite, and nitrite (NOx) plasma level, a ratio of free hydrogen sulfide plasma level to total NOx plasma level, and a ratio of total hydrogen sulfide metabolite plasma level and total NOx plasma level, diagnosing the patient with as having CLI based on the patient indicator value, and administering to the patient a therapeutic for CLI.

公开(公告)号：US20200038342A1

公开(公告)日：2020-02-06

申请号：US16377723

申请日：2019-04-08

Applicant: Catabasis Pharmaceuticals, Inc.

Inventor： Chi B. Vu ,  Michael R. Jirousek

IPC: A61K31/105 ,  A61K31/095 ,  A61K31/4406 ,  C07D213/82 ,  A61K47/54 ,  A61K31/121 ,  A61K31/195 ,  A61K45/06 ,  C07C323/23

Abstract: The invention relates to fatty acid cysteamine conjugates, compositions comprising a fatty acid cysteamine conjugate, and methods for using such conjugates and compositions to treat disease, such as a disease caused by dysregulation of autophagy.

公开(公告)号：US10039738B2

公开(公告)日：2018-08-07

申请号：US14143079

申请日：2013-12-30

Applicant: United Arab Emirates University

Inventor： Salim M. A. Bastaki

IPC: A61K31/352 ,  A61K31/10 ,  A61K31/105

Abstract: The present invention relates to the treatment of peptic ulcers. In particular, the present invention provides methods and compositions for the treatment of peptic ulcers. In addition, the present invention provides a method of reducing gastric acid secretion in a subject.

公开(公告)号：US20180133170A1

公开(公告)日：2018-05-17

申请号：US15639776

申请日：2017-06-30

Applicant: Hydra Biosciences, Inc.

Inventor： Manfred Weigele ,  Jayhong A. Chong ,  Glenn R. Larsen ,  Neil J. Hayward ,  Amy Ripka ,  Howard Ng ,  Magdalene M. Moran ,  Christopher Fanger ,  Donato Del Camino ,  Steven P. Adams

IPC: A61K31/105 ,  C07D487/04 ,  A61K31/11

Abstract: Compounds and compositions for treating disorders related to TRPA1 are described herein.